{"symbol":"SZ002262","secucode":"002262.SZ","items":[{"title":"恩华药业：关于盐酸多沙普仑注射液通过仿制药一致性评价的公告","summary":"证券日报网讯6月9日，恩华药业发布公告称，公司于近日收到国家药品监督管理局核准签发的关于盐酸多沙普仑注射液的《药品补充申请批准通知书》，批准该药品通过仿制药质量和疗效一致性评价（简称“一致性评价”）。","source":null,"url":"http://finance.eastmoney.com/news/1354,202606093765386636.html","info_code":"NW202606093765386636","show_time_timestamp":1781010300000,"show_time":"2026-06-09 21:05:00","publish_time_timestamp":0,"publish_time":"","update_time_timestamp":0,"update_time":"","raw":{"uniqueUrl":"http://finance.eastmoney.com/a/202606093765386636.html","url":"http://finance.eastmoney.com/news/1354,202606093765386636.html","code":"202606093765386636","infoCode":"NW202606093765386636","recordId":null,"source":null,"title":"恩华药业：关于盐酸多沙普仑注射液通过仿制药一致性评价的公告","updateTime":0,"showDateTime":1781010300000,"publishDate":0,"sRatingName":null,"summary":"证券日报网讯6月9日，恩华药业发布公告称，公司于近日收到国家药品监督管理局核准签发的关于盐酸多沙普仑注射液的《药品补充申请批准通知书》，批准该药品通过仿制药质量和疗效一致性评价（简称“一致性评价”）。"}},{"title":"超品种生产、超范围存储，恩华药业原料药基地再遭重罚","summary":"6月8日晚，江苏恩华药业股份有限公司（简称“恩华药业”）发布公告称，旗下贾汪分公司收到徐州市贾汪区应急管理局行政处罚决定书。因被中央安全生产考核巡查组查实存在超品种生产、超范围存储等安全隐患，该分公司被合并处以49.17万元罚款。此前贾汪分公司在安全生产、生态环保、药品质量等多个领域频现问题。","source":null,"url":"http://finance.eastmoney.com/news/1354,202606093765251472.html","info_code":"NW202606093765251472","show_time_timestamp":1781000940000,"show_time":"2026-06-09 18:29:00","publish_time_timestamp":0,"publish_time":"","update_time_timestamp":0,"update_time":"","raw":{"uniqueUrl":"http://finance.eastmoney.com/a/202606093765251472.html","url":"http://finance.eastmoney.com/news/1354,202606093765251472.html","code":"202606093765251472","infoCode":"NW202606093765251472","recordId":null,"source":null,"title":"超品种生产、超范围存储，恩华药业原料药基地再遭重罚","updateTime":0,"showDateTime":1781000940000,"publishDate":0,"sRatingName":null,"summary":"6月8日晚，江苏恩华药业股份有限公司（简称“恩华药业”）发布公告称，旗下贾汪分公司收到徐州市贾汪区应急管理局行政处罚决定书。因被中央安全生产考核巡查组查实存在超品种生产、超范围存储等安全隐患，该分公司被合并处以49.17万元罚款。此前贾汪分公司在安全生产、生态环保、药品质量等多个领域频现问题。"}},{"title":"恩华药业(002262.SZ)：盐酸多沙普仑注射液（5ml:100mg）通过仿制药一致性评价","summary":"2026年6月9日，江苏恩华药业股份有限公司（002262.SZ）发布公告称，公司近日收到国家药品监督管理局核准签发的盐酸多沙普仑注射液《药品补充申请批准通知书》，该药品通过仿制药质量和疗效一致性评价。规格为5ml:100mg，注册分类为化学药品。盐酸多沙普仑注射液用于呼吸衰竭。公司在该产品的一致性评价项目上已投入研发费用约200万元。","source":null,"url":"http://finance.eastmoney.com/news/1354,202606093765136750.html","info_code":"NW202606093765136750","show_time_timestamp":1780993285000,"show_time":"2026-06-09 16:21:25","publish_time_timestamp":0,"publish_time":"","update_time_timestamp":0,"update_time":"","raw":{"uniqueUrl":"http://finance.eastmoney.com/a/202606093765136750.html","url":"http://finance.eastmoney.com/news/1354,202606093765136750.html","code":"202606093765136750","infoCode":"NW202606093765136750","recordId":null,"source":null,"title":"恩华药业(002262.SZ)：盐酸多沙普仑注射液（5ml:100mg）通过仿制药一致性评价","updateTime":0,"showDateTime":1780993285000,"publishDate":0,"sRatingName":null,"summary":"2026年6月9日，江苏恩华药业股份有限公司（002262.SZ）发布公告称，公司近日收到国家药品监督管理局核准签发的盐酸多沙普仑注射液《药品补充申请批准通知书》，该药品通过仿制药质量和疗效一致性评价。规格为5ml:100mg，注册分类为化学药品。盐酸多沙普仑注射液用于呼吸衰竭。公司在该产品的一致性评价项目上已投入研发费用约200万元。"}},{"title":"恩华药业：公司盐酸多沙普仑注射液通过仿制药一致性评价","summary":"恩华药业6月9日公告，公司于近日收到国家药品监督管理局核准签发的关于盐酸多沙普仑注射液的《药品补充申请批准通知书》，批准该药品通过仿制药质量和疗效一致性评价。盐酸多沙普仑注射液用于呼吸衰竭。公司在该产品的一致性评价项目上已投入研发费用约200万元人民币。","source":null,"url":"http://finance.eastmoney.com/news/1354,202606093765106050.html","info_code":"NW202606093765106050","show_time_timestamp":1780991351000,"show_time":"2026-06-09 15:49:11","publish_time_timestamp":0,"publish_time":"","update_time_timestamp":0,"update_time":"","raw":{"uniqueUrl":"http://finance.eastmoney.com/a/202606093765106050.html","url":"http://finance.eastmoney.com/news/1354,202606093765106050.html","code":"202606093765106050","infoCode":"NW202606093765106050","recordId":null,"source":null,"title":"恩华药业：公司盐酸多沙普仑注射液通过仿制药一致性评价","updateTime":0,"showDateTime":1780991351000,"publishDate":0,"sRatingName":null,"summary":"恩华药业6月9日公告，公司于近日收到国家药品监督管理局核准签发的关于盐酸多沙普仑注射液的《药品补充申请批准通知书》，批准该药品通过仿制药质量和疗效一致性评价。盐酸多沙普仑注射液用于呼吸衰竭。公司在该产品的一致性评价项目上已投入研发费用约200万元人民币。"}},{"title":"恩华药业：盐酸多沙普仑注射液通过仿制药一致性评价","summary":"恩华药业(002262.SZ)公告称，公司近日收到国家药监局核准签发的《药品补充申请批准通知书》，批准盐酸多沙普仑注射液通过仿制药质量和疗效一致性评价。该药品用于呼吸衰竭，公司已投入研发费用约200万元。通过一致性评价将有利于提升市场竞争力，对公司经营业绩产生积极影响。","source":null,"url":"http://finance.eastmoney.com/news/1354,202606093765102650.html","info_code":"NW202606093765102650","show_time_timestamp":1780991162000,"show_time":"2026-06-09 15:46:02","publish_time_timestamp":0,"publish_time":"","update_time_timestamp":0,"update_time":"","raw":{"uniqueUrl":"http://finance.eastmoney.com/a/202606093765102650.html","url":"http://finance.eastmoney.com/news/1354,202606093765102650.html","code":"202606093765102650","infoCode":"NW202606093765102650","recordId":null,"source":null,"title":"恩华药业：盐酸多沙普仑注射液通过仿制药一致性评价","updateTime":0,"showDateTime":1780991162000,"publishDate":0,"sRatingName":null,"summary":"恩华药业(002262.SZ)公告称，公司近日收到国家药监局核准签发的《药品补充申请批准通知书》，批准盐酸多沙普仑注射液通过仿制药质量和疗效一致性评价。该药品用于呼吸衰竭，公司已投入研发费用约200万元。通过一致性评价将有利于提升市场竞争力，对公司经营业绩产生积极影响。"}}]}